NASDAQ · EPIX
Healthcare · Biotechnology
$0.20
Down-$0.00 (-1.85%)
Updated Aug 15, 2026, 1:06 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
EPIX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning EPIX.
EPIX research
Company profile and research snapshot.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 4, 2024 | Oppenheimer | Perform | — |
| Nov 4, 2024 | Piper Sandler | Neutral | — |
| Nov 1, 2024 | Jones Trading | Hold | — |
| May 16, 2024 | Oppenheimer | Outperform | — |
| Dec 13, 2023 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
prnewswire.com · Oct 9, 2025
SOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada , Oct. 9, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") today announced the completion of XenoTherapeutics' ("Xeno") previously announced acquisition of ESSA (the "Acquisition").
prnewswire.com · Oct 6, 2025
SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada , Oct. 6, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") is pleased to announce that its Securityholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the "Common Shares" and the holders of such Common Shares, the "Shareholders") by XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company, by way of a statutory plan of arrangement (the "Transaction" or the "Arrangement") at the special meeting of Securityholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 99.83% of the votes cast by Shareholders present in person or represented by proxy at the Meeting, (ii) 99.85% of the votes cast by Shareholders, holders of options to purchase Common Shares of the Company, holders of pre-funded Common Share purchase warrants of the Company (collectively, the "Securityholders"), present in person or represented by proxy at the Meeting, voting together as a single class, and (iii) 99.48% of the votes cast by Shareholders, present in person or represented by proxy at the Meeting, excluding for this purpose the votes required to be excluded pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EPIX.
No results
No recent SID articles mention EPIX.
